Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

130.00EUR
8:15am EDT
Change (% chg)

€2.65 (+2.08%)
Prev Close
€127.35
Open
€127.60
Day's High
€130.50
Day's Low
€127.35
Volume
844,279
Avg. Vol
2,415,320
52-wk High
€146.45
52-wk Low
€94.22

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three subgroups: HealthCare, involved in the research, development and production of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control, and... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €105,311.80
Shares Outstanding(Mil.): 826.95
Dividend: 2.25
Yield (%): 1.77

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 31.85 36.91 40.75
EPS (TTM): 4.00 -- --
ROI: 6.84 16.39 15.62
ROE: 15.47 17.22 16.71
Search Stocks

BRIEF-Bayer and Sprint Bioscience collaborate in cancer research

* Bayer Healthcare enters into collaboration with Sprint Bioscience on tumor metabolism program

2:44am EDT

European Factors to Watch-Shares seen higher, focus on earnings

LONDON, July 28 - European equities headed for a higher open on Tuesday after falling in the previous five sessions, with some strong company results and mergers and acquisitions news seen supporting the market.

2:41am EDT

Glenmark Pharmaceuticals' Finacea generic infringes Bayer patent: court

NEW YORK - India's Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a U.S. court ruled on Monday.

27 Jul 2015

Glenmark Pharmaceuticals' Finacea generic infringes Bayer patent - court

NEW YORK, July 27 - India's Glenmark Pharmaceuticals' proposed generic version of Bayer AG's Finacea, a gel for treating the common skin condition rosacea, infringes Bayer's patent, a U.S. court ruled on Monday.

27 Jul 2015

Deals of the day- Mergers and acquisitions

July 17 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

17 Jul 2015

Bayer to talk to investors over summer on Covestro flotation: sources

FRANKFURT - German drugmaker Bayer plans to hold investor meetings over the summer as it prepares a stock market listing of its plastics division, sources familiar with the deal said.

17 Jul 2015

Bayer to talk to investors over summer on Covestro flotation - sources

FRANKFURT, July 17 - German drugmaker Bayer plans to hold investor meetings over the summer as it prepares a stock market listing of its plastics division, sources familiar with the deal said.

17 Jul 2015

FDA OKs second test to see if Essure contraceptive is placed right

- Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company's Essure permanent birth control device has been placed properly.

01 Jul 2015

FDA OKs second test to see if Essure contraceptive is placed right

July 1 - Bayer Healthcare said on Wednesday the U.S. Food and Drug Administration approved using transvaginal ultrasound as an alternate test to confirm if the company's Essure permanent birth control device has been placed properly.

01 Jul 2015

BRIEF-Bayer submits application for recombinant factor compound in Japan

* Bayer submits an application for market authorization of recombinant factor VIII product as a treatment of hemophilia a in Japan Further company coverage:

30 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks